Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

The benefits of using NAVA on all preterm infants

Dr. Juyoung Lee, pediatrician in the Division of Neonatology at the Inha University College of Medicine in the Republic of Korea, routinely use Getinge’s innovation Neurally Adjusted Ventilatory Assist (NAVA) with diaphragm monitoring (Edi) on all preterm infants born in her unit. “We are applying NAVA from the first days of life, and the results are amazing. I don’t observe any severe cases of the chronic lung disease bronchopulmonary dysplasia (BPD), and some infants born in the 23[d] week with a weight of 500 grams can be weaned off invasive ventilation already after two weeks.

Application for Block Listing

EnQuest PLC24 November 2023 Application for Block Listing EnQuest PLC (the "Company") has today made applications to the Financial Conduct Authority ("FCA") and the London Stock Exchange ("LSE") for 30,000,000 ordinary shares of 5p each (the "New Shares") to be admitted to the Official List of the FCA and admitted to trading on the premium segment of the LSE's main market for listed securities. Admission is expected to take place on 27 November 2023. The New Shares are being reserved under a block listing and may be issued when required to satisfy the exercise of options and

Monthly Summary

FIDELITY EMERGING MARKETS LIMITED (the ‘Company’)   Legal Entity Identifier (LEI): 213800HWWQPUJ4K1GS84   Availability of the Monthly Factsheet (Summary) as at 31 October 2023   Copies of the above document have been submitted to the UK Listing Authority, and will shortly be available for inspection on the National Storage Mechanism (NSM):   https://data.fca.org.uk/#/nsm/nationalstoragemechanism   The factsheet is also available on the Company's website: www.fidelity.co.uk/emergingmarkets   The latest disclosable full portfolio is available on request.

BioStock: Ultimovacs CEO - "Data could put us at the forefront of cancer vaccine field"

Ultimovacs has announced positive survival data from the phase II NIPU trial assessing the universal cancer vaccine UV1 in malignant mesothelioma. The company’s CEO Carlos de Sousa talked to BioStock about the results and what they mean for the oncology field.Watch the interview with Carlos de Sousa at biostock.se https://www.biostock.se/en/2023/11/data-could-put-ultimovacs-at-the-forefront-of-cancer-vaccine-field/This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 205 - 24 NOVEMBER 2023   In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 186/23 and 187/23.   Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Stig Frederiksen, Head of Investor Relations, tel.: +45 32 71 08 55, e-mail: sfr@norden.com

NYAB Oyj - Managers' Transactions

NYAB PlcMANAGERS' TRANSACTIONS24 November 2023 at 10:20NYAB Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: Johan LarssonPosition: Chief Executive Officer Issuer: NYAB OyjLEI: 743700UX7WTIOT3QO547Notification type: INITIAL NOTIFICATIONReference number: 44399/4/4 ____________________________________________Transaction date: 2023-11-23Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)Instrument type: SHAREISIN: FI4000153515Nature of transaction: ACQUISITION  Transaction details(1):

NYAB Oyj - Managers' Transactions

NYAB PlcMANAGERS' TRANSACTIONS24 November 2023 at 10:15NYAB Oyj - Managers' Transactions____________________________________________Person subject to the notification requirementName: BINGAB Barents Investment Group ABPosition: Closely associated person(X) Legal person (1):Person Discharging Managerial Responsibilities In IssuerName: Johan LarssonPosition: Chief Executive OfficerIssuer: NYAB OyjLEI: 743700UX7WTIOT3QO547Notification type: INITIAL NOTIFICATIONReference number: 44396/4/6 ____________________________________________Transaction date: 2023-11-20

SFR Research: Mandatum ranked second best institutional wealth manager in Finland

Mandatum has improved its overall rating more than any other asset manager in Finland this decade.Mandatum has been awarded with the Gold Award in Scandinavian Financial Research’s “Institutional Investment Services, Finland 2023” customer study. In the study, approximately 100 Finnish institutional investors evaluated 18 asset management service providers with nine quality criteria. Mandatum ranked second in the “Large” service provider group with a total score of 4.01 out of 5. Mandatum received particular praise for its customer service, investment performance over the short and long

Company Announcement no. 109, 2023 – Nordea Kredit Realkreditaktieselskab drawings as per 1 January 2024

Nordea Kredit hereby announces drawings data for callable covered mortgage bonds (SDRO) as per 1 January 2024. The figures are published in order to comply with publication requirements in the transparency regulation 2017/1129/EU and the Danish Act on Capital Markets section 24.   Questions can be directed to Torben Jurlander phone +45 55 47 41 99.     Yours faithfully   Nordea Kredit Realkreditaktieselskab

Tietoevry’s financial calendar 2024

Tietoevry Corporation     STOCK EXCHANGE RELEASE     24 November 2023 10:00 a.m. EET   15 Interim report 4/2023 and financial statements bulletin for 2023February  (9:00 a.m. EET)15 Financial Review, incl. Financial Statements, Report by the BoardFebruary of Directors and Corporate Governance Statement for 202329 Annual Report 2023February13 March Annual General Meeting   Tietoevry will publish three interim reports in 2024:   25 April Interim report 1/2024 (9:00 a.m. EEST)23 July Interim report 2/2024 (9:00 a.m. EEST)

Clean Industry Solutions Holding Europe AB: Quarterly Report July-September 2023

Q3 from 01-07-2023 to 30-09-2023 (01-07-2022 to 30-09-2022), 01-09 from 01-01-2023 to 30-09-2023 (01-01-2022 to 30-09-2022), FY from 01-01-2022 to 31-12-2022 The report can be found here:https://cleanindustrysolutions.com/en/investor-relations/financial-reports/The period in brief – financial summary for the third quarter · Income amounted to SEK 1.3 million · Other operating income amounted to SEK 3.4 million · Operating Expenses for the third quarter amounted to SEK -7.8 million · Operating result (EBIT) for the third quarter amounted to SEK -5.9 million · Earnings per

Calliditas’ partner Everest Medicines announces China NMPA’s approval of Nefecon® for the treatment of primary IgA nephropathy

Calliditas Therapeutics AB (Nasdaq: CALT, Nasdaq Stockholm: CALTX) (“Calliditas”) today announced that its partner Everest Medicines (HKEX: 1952.HK) ("Everest") announced that China's National Medical Products Administration (NMPA) has approved Nefecon® for the treatment of primary immunoglobulin A nephropathy (IgAN) in adults at risk of disease progression.China has the highest prevalence of primary glomerular diseases in the world with an estimated five million IgAN patients. There is a very significant unmet medical need for novel therapies among IgAN patients in China and other Asian

GARO to divest industrial property in Poland for MSEK 45 generating a capital gain of MSEK 17

GARO is thereby completing the final step of its strategic plan to create modern and efficient volume production in Poland for our new product program for destination charging – GARO Entity.GARO Entity – the future-proof platform for destination chargingDeliveries of GARO Entity Compact, the electric car charger designed primarily for home charging, commenced at the start of October, meaning that together with GARO Entity Pro, GARO offers a total product range in destination charging. GARO Entity is future-proof to new technology and has open APIs for various types of integrations and

President and CEO Mats Rahmström will leave Atlas Copco Group, April 30, 2024

Nacka, Sweden, November 24, 2023: After 35 years with the Group, and almost seven years as CEO, Mats Rahmström has informed the Board of Directors of Atlas Copco AB that he wishes to step down. Mats Rahmström will leave Atlas Copco and its Board, April 30[th] 2024.“Mats has, through his dedication and leadership, played a very important role in successfully developing Atlas Copco Group and take it to its current strong position,” said Hans Stråberg, Chairman of the Board. “Mats really embodies the Group’s values and during his tenure as CEO, we’ve seen impressive growth and financial

ANNOUNCEMENT OF RESULTS OF TENDER OFFERS

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES OF AMERICA AND THE DISTRICT OF COLUMBIA (the "United States") OR TO ANY U.S. PERSON (AS DEFINED IN THE TENDER OFFER MEMORANDUM) OR IN OR INTO ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS DOCUMENT.On 16 November 2023, Samhällsbyggnadsbolaget i Norden AB

Akiram Therapeutics’ pioneering cancer research backed by SEK 6 million from the Erling-Persson Foundation

Akiram Therapeutics, a Swedish biotech company specializing in targeted radiotherapy, is pleased to announce that the company’s founder, Professor Marika Nestor and her research group at Uppsala University have been granted SEK 6 million by the Erling-Persson Foundation. This funding will advance a groundbreaking research project aimed at developing novel radiopharmaceuticals for the treatment of aggressive cancers and bolster Akiram’s upcoming Phase I first-in-human human study scheduled for 2024.Akiram Therapeutics has developed a novel targeted radioimmunotherapy called [177]Lu-AKIR001.

Scania turns green supply target into requirements

Determined to use its spending power to drive the shift towards a sustainable transport system, Scania now turns its supply chain decarbonisation target into mandatory purchasing requirements.“We are excited to announce this transformative move, prepared in close collaboration with our suppliers and partners. Implementing green purchasing requirements is both a question of making sustainable transport a reality and ensuring access to low-carbon material in a rapidly increasing competition”, says Christian Levin, CEO at Scania.  Scania has introduced an industry-leading strategy to

Essity joins European research project on circular sensor technology

The hygiene and health company Essity has joined the European research project Sustronics, which is supporting the development of circular electronic products. Companies and universities from 11 countries will, together with Essity, develop sensor-based digital solutions for self and professional care.The main purpose of Sustronics is to transform the European electronics industry and promote a more circular economy through the use of eco-design, bio-based materials and energy-efficient manufacturing. As part of the project, electronic products will be redesigned to become circular,

Scandic to rebrand hotel in central Helsinki

Scandic Hotels has signed a long-term agreement with landlord Exilion to extend the agreement and rebrand the Holiday Inn City Centre in downtown Helsinki. Since acquiring Restel in 2017, Scandic has operated the hotel under a lease agreement with Exilion and a franchise agreement with IHG. From 2025, the hotel will be operated under the Scandic brand.Today, Holiday Inn City Centre has 174 rooms and a strategically advantageous location next to Helsinki Central Station. As part of the extension agreement, the landlord has undertaken to completely renovate the hotel. Renovation work is

Neste to introduce solar power to its Porvoo refinery

Neste Corporation, News, 24 November 2023Neste has signed a purchase agreement for solar power supply to its Porvoo refinery in Finland with the renewable energy company CPC Finland Oy.  Solar power supply from the Lakari solar plant in Rauma, Finland is expected to start in spring 2024. Once ready, the plant will be the largest operating solar plant in Finland. The total annual volume of the agreement is approximately 24 GWh, which represents 75% of the annual capacity of the Lakari solar plant in Rauma.  “Neste’s agreement on solar power is a valuable addition to our

Peab builds senior living in Stenungsund

Peab has been commissioned to build Hasselhöjden, a senior living facility in Stenungsund. The customer is Stenungsund Municipality and the contract is worth SEK 188 million.On behalf of Stenungsund Municipality Peab will build a new senior living facility at Hasselhöjden in Stenungsund. The five story building will consist of 104 apartments and personnel rooms. “We look forward to getting started on the construction at Hasselhöjden. This will be a substantial and much longed for addition to our existing senior living facilities. At Hasselhöjden we will be able to offer seniors a modern

There are no items matching the current filter
There are no more items matching the current filter
Back to top